Bausch Health Expands OraPharma Reach to Canada and Puerto Rico

Bausch Health Companies Inc. and its dental branch, OraPharma, have announced the expansion of OraPharma into Canada and Puerto Rico. This move aims to increase access to treatment options for periodontal disease and strengthen collaboration with dental professionals.

Periodontal disease affects a vast number of individuals worldwide. In Canada, it is estimated that seven in ten adults will experience gum disease in their lifetime. Similarly, 44.5% of older adults in Puerto Rico suffer from moderate to severe periodontal disease. This expansion addresses the need for better awareness and access to treatment.

OraPharma’s Arestin®, the only FDA-approved locally applied antibiotic for periodontitis, plays a key role in this initiative. This antibiotic, combined with scaling and root planing procedures, is designed to aid dental professionals in managing adult periodontitis more effectively.